Table 2.

Factors associated with MBM overall survival.

				Unadjusted			Adjusted*
Variable	Level	N	%	HR	95% CI	p-value	HR	95% CI	p-value
Age at MBM Diagnosis	continuous	425	100	1.007	0.999–1.014	0.08
Dominant BM size (cm)	continuous	425	100	0.99	0.91–1.08	0.84
Year of MBM Diagnosis	continuous	425	100	0.92	0.87–0.96	0.0004	0.92	0.87–0.97	0.0008
Serum LDH	Within normal limits	134	32	ref			ref
	Above normal limits	99	23	2.14	1.59–2.87	<0.0001	2.14	1.58–2.88	<0.0001
Number of BM at Diagnosis	continuous	425	100	1.03	1.02–1.04	<0.0001	1.03	1.01–1.04	<0.0001
Gender	Female	121	48	ref
	Male	304	72	1.00	0.78–1.27	0.98
Presenting Symptom	Asymptomatic	166	39	ref
	Headache	72	17	0.90	0.65–1.23	0.49
	Motor/sensory	83	20	1.06	0.79–1.43	0.70
	Seizure	34	8	0.98	0.63–1.52	0.93
	Mental status change	56	13	1.15	0.82–1.62	0.42
	Other	14	3	0.90	0.44–1.84	0.77
Hemorrhage Present in BM at Diagnosis	No	177	42	ref
	Yes	248	58	1.04	0.83–1.30	0.73
LMD	No	363	85	ref			ref
	Yes (time-dependent variable)	62	15	3.59	2.69–4.78	<0.0001	3.63	2.71–4.87	<0.0001
BRAF Status	Wildtype	184	43	ref
	Mutated	206	48	0.98	0.78–1.23	0.87
Pre-BM Immunotherapy	No	226	53	ref			ref
	Yes	199	47	1.34	1.08–1.67	0.0089	1.40	1.12–1.75	0.003
Systemic Burden at BM	No extracranial disease	42	10	ref			ref
	Extracranial disease present	372	88	1.97	1.28–3.04	0.002	1.67	1.07–2.60	0.02

^*Variables significant in the unadjusted models were brought forward.